232 related articles for article (PubMed ID: 31292271)
21. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
22. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
23. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
24. CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database.
Kobayashi K; Saito Y; Kage H; Fukuoka O; Yamamura K; Mukai T; Oda K; Yamasoba T
Jpn J Clin Oncol; 2023 Aug; 53(9):798-807. PubMed ID: 37357968
[TBL] [Abstract][Full Text] [Related]
25. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
26. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
[TBL] [Abstract][Full Text] [Related]
27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
28. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract][Full Text] [Related]
29. A systematic comparison of copy number alterations in four types of female cancer.
Kaveh F; Baumbusch LO; Nebdal D; Børresen-Dale AL; Lingjærde OC; Edvardsen H; Kristensen VN; Solvang HK
BMC Cancer; 2016 Nov; 16(1):913. PubMed ID: 27876019
[TBL] [Abstract][Full Text] [Related]
30. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
[TBL] [Abstract][Full Text] [Related]
31. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
32. Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Eeckhoutte A; Saint-Ghislain M; Reverdy M; Raynal V; Baulande S; Bataillon G; Golmard L; Stoppa-Lyonnet D; Popova T; Houdayer C; Manié E; Stern MH
Fam Cancer; 2020 Jul; 19(3):203-209. PubMed ID: 32172432
[TBL] [Abstract][Full Text] [Related]
33. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
[TBL] [Abstract][Full Text] [Related]
34. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
35. CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract][Full Text] [Related]
36.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
37. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract][Full Text] [Related]
38. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations.
Menghi F; Barthel FP; Yadav V; Tang M; Ji B; Tang Z; Carter GW; Ruan Y; Scully R; Verhaak RGW; Jonkers J; Liu ET
Cancer Cell; 2018 Aug; 34(2):197-210.e5. PubMed ID: 30017478
[TBL] [Abstract][Full Text] [Related]
39. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
[TBL] [Abstract][Full Text] [Related]
40. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
